---
document_datetime: 2023-10-31 11:12:00
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/biopoin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: biopoin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.2049939
conversion_datetime: 2025-12-26 18:57:56.669429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Biopoin

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0053              | A.7 - Administrative change - Deletion of manufacturing sites | 26/09/2023                          |                                             | Annex II and PL                  |           |
| IB/0052              | B.I.z - Quality change - Active substance - Other variation   | 29/11/2022                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0051             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                 | 05/01/2022   |     | Labelling and PL   |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------------------|-----------------------------------|
| PSUSA/1240/ 202104 | Periodic Safety Update EU Single assessment - epoetin theta                                                                                                                                                                                                                                                                                                                                                                                                                                      | 02/12/2021   | n/a |                    | PRAC Recommendation - maintenance |
| IB/0049            | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                          | 11/10/2021   | n/a |                    |                                   |
| II/0048            | B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                                                                                                                     | 22/07/2021   | n/a |                    |                                   |
| IA/0047/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 15/07/2020   | n/a |                    |                                   |
| IB/0046/G          | This was an application for a group of variations. B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                   | 28/11/2019   | n/a |                    |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.z - Change in manufacture of the AS - Other variation                                                                                                                                                                                                   |            |            |                 |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/1240/ 201804 | Periodic Safety Update EU Single assessment - epoetin theta                                                                                                                                                                                                   | 29/11/2018 | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0045            | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                  | 23/11/2018 | n/a        |                 |                                   |
| IAIN/0043          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                        | 23/03/2018 | 23/01/2019 | Annex II and PL |                                   |
| IB/0042            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                | 07/11/2017 | 23/01/2019 | SmPC and PL     |                                   |
| IB/0041            | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                       | 05/07/2017 | n/a        |                 |                                   |
| II/0036/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 05/05/2017 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|             | excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method   |            |            |                 | manufacturer of a novel   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------|
| IB/0040     | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                           | 19/04/2017 | n/a        |                 |                           |
| IB/0037     | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                             | 03/03/2017 | n/a        |                 |                           |
| IA/0039     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                | 07/02/2017 | n/a        |                 |                           |
| IB/0038     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                 | 20/01/2017 | n/a        |                 |                           |
| IAIN/0035/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                        | 08/07/2016 | 12/06/2017 | Annex II and PL |                           |

<div style=\"page-break-after: always\"></div>

|           | or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                    |            |            |                    |              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|--------------|
| IA/0034   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a                                                                                                                                                                               | 08/07/2016 | n/a        |                    | Member State |
| IA/0033   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                                                                                                  | 08/07/2016 | n/a        |                    |              |
| IB/0032/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 24/06/2016 | 12/06/2017 | SmPC and Labelling |              |
| IB/0031   | B.I.a.4.z - Change to in-process tests or limits                                                                                                                                                                                                                                                                                                                                       | 29/04/2016 | n/a        |                    |              |

<div style=\"page-break-after: always\"></div>

|                    | applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0030            | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/02/2016 | n/a        |                        |                                                                                                                                           |
| PSUSA/1240/ 201504 | Periodic Safety Update EU Single assessment - epoetin theta                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/12/2015 | 18/02/2016 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1240/201504. |
| IAIN/0029/G        | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within | 21/12/2015 |            | SmPC, Labelling and PL |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in tablets, ampoules, etc.) the range of the currently B.II.e.5.a.1 - Change product - Change in   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                                                                   |            |            |             |                       |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------|
| IB/0028/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where takes place | 12/10/2015 | n/a        |             | batch control/testing |
| IB/0027   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                     | 04/09/2015 | n/a        |             |                       |
| IA/0026   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                         | 14/08/2015 | n/a        |             |                       |
| IB/0024   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/07/2015 | 25/08/2015 | SmPC and PL |                       |

<div style=\"page-break-after: always\"></div>

|             | concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                        |            |            |                        |                                                                                                                                                                                                                                                                                      |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0023     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                        | 25/06/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                      |
| R/0020      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                              | 26/06/2014 | 26/08/2014 | SmPC, Labelling and PL | Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of Biopoin continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. |
| IAIN/0022/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                  | 12/08/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                      |
| IB/0021/G   | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol | 31/07/2014 | n/a        |                        |                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IA/0019   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                               | 11/12/2013   | n/a        |                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|
| IB/0018   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 27/11/2013   | 26/08/2014 | SmPC, Annex II and PL  |
| IB/0016   | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                         | 05/11/2013   | n/a        |                        |
| IA/0017   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 25/10/2013   | n/a        |                        |
| T/0015    | Transfer of Marketing Authorisation                                                                                                                                                                                                          | 16/08/2013   | 09/10/2013 |                        |
| IB/0014   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                         | 16/08/2013   | n/a        |                        |
| IAIN/0013 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                               | 18/06/2013   | n/a        |                        |
| IB/0011   | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                          | 20/12/2012   | 09/10/2013 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| IB/0010   | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                  | 08/06/2012   | n/a        |                        |             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------|
| IB/0009   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 08/06/2012   | n/a        |                        |             |
| IA/0008/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect information | 13/04/2012   | n/a        |                        | the product |
| IAIN/0007 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 01/03/2012   | 10/10/2012 | SmPC, Labelling and PL |             |
| II/0005   | to increase the batch size of active substance manufacturing. B.I.a.3.c - Change in batch size (including batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/10/2011   | 20/10/2011 |                        |             |

<div style=\"page-break-after: always\"></div>

|           | ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS                                                                                                                                                                                                                                                                         |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                             | 14/10/2011 | n/a        | PL       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0004   | Introduction of a new Pharmacovigilance System (TEVA DDPS Version 10), including a new Qualified person for Pharmacovigilance. Annex II.B has also been updated with the latest wording as per October 2010 CHMP procedural announcement. C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH | 23/06/2011 | 05/08/2011 | Annex II | The MAH has introduced a new pharmacovigilance system used by TEVA Pharmaceutical Industries Ltd., which will be applied for the product Biopoin. The detailed description of this pharmacovigilance system includes information pertaining to the qualified person responsible for pharmacovigilance, the global structure of the pharmacovigilance organisation, company procedures relating to pharmacovigilance activities, global safety databases, links with other organisations, training and the quality management system. The MAH has also taken the opportunity to update Annex II.B with the latest wording as per October 2010 CHMP procedural announcement. |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                             | 28/03/2011 | n/a        | PL       | Update of Package Leaflet to add the list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0002/G | This was an application for a group of variations. To include the results from the Cochrane meta- analysis in section 5.1 and information on the PRCA in patients with Hepatitis C in section 4.4 of the SmPC. Additionally the MAH took this opportunity to make minor linguistic amendments to the following languages BG, CS, ET, FI, FR, LV, NL, NO and RO.                              | 22/07/2010 | n/a        | SmPC     | To update Section 5.1 \"Pharmacodynamic properties\" of the SmPC with the following wording: A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio- ,chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH   |            |            |                    | chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). Meta- analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4). To update Section 4.4 \"Special Warnings and Precautions of Use\" of the SmPC with the following wording: A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing. Cases have been reported in patients with hepatitis C treated with interferon and ribavirin, when epoetins are used concomitantly. Epoetins are not approved in the management of anaemia associated with hepatitis C.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001 | To extent the drug product shelf life. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/01/2010 | 15/03/2010 | SmPC and Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |